Differences and comparative analysis of efficacy between acalatinib and zanubrutinib

Acalabrutinib, also known as acalabrutinib in China) and zanubrutinib (Zanubrutinib) are both new generation Bruton's tyrosine kinase inhibitors (BTK inhibitor agent), mainly used to treat a variety of B cell malignant tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), etc. Because these two drugs have the same target and are oral small molecule targeted drugs, they are often used by patients and clinicians to compare their efficacy and safety. This article will provide a detailed analysis of the similarities and differences between acotinib and zanubrutinib in terms of drug sources, molecular mechanisms, efficacy data, safety features, and indication coverage, etc., to help patients better understand the basis for choosing these two drugs.

1. Drug sources and research and development background

Acotinib was developed by AstraZeneca (AstraZeneca) in the United States. As an improved version of ibrutinib (Ibrutinib), it was approved by the U.S. FDAFDA in 2017. Its original design is to optimize the selectivity of BTK inhibition and reduce interference with other kinases (such as EGFR, ITK, etc.), thereby reducing side effects.

Zarubrutinib is a BTK inhibitor independently developed by China's BeiGene (BeiGene). It is the first targeted drug led by a local Chinese company and approved by the U.S. FDA for marketing. It was approved for the treatment of mantle cell lymphoma in the United States in 2019, and was subsequently expanded to CLL/SLL and other indications.

Therefore, from the perspective of drug sources, acotinib is the original drug of a large international pharmaceutical company, while zanubrutinib is an innovative drug independently developed by Chinese companies and recognized globally.

2. Comparison of pharmacological mechanisms and molecular properties

What acotinib and zanubrutinib have in common is that they can irreversibly bind to BTK protein, inhibit the B cell receptor signaling pathway, thereby inhibiting the malignant proliferation of B cells. Both are more selective than the first-generation BTK inhibitor ibrutinib and act less on non-target kinases.

1.Features of acotinib:

Highly selective inhibitionBTK, but not significantly inhibiting EGFR, ITK, etc.

The biological half-life is short and it needs to be administered twice daily (100mg twice daily).

The pharmacokinetics are stable and suitable for long-term treatment.

2.Characteristics of zanubrutinib:

It is also highly selectiveBTK and has less impact on EGFR.

High bioavailability, flexible dosage (160mgdaily2times, or 320mgdaily1times).

It has good central penetration ability and is active in meningeal invasive diseases.

In summary, the two are very similar at the molecular level, and both are highly selective BTK inhibitors. However, zanubrutinib has certain advantages in dosage flexibility and tissue distribution.

3. Comparison of efficacy: CLL/SLL and MCL application

Both have shown good efficacy in the treatment ofCLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma).

1.Acotinib efficacy data (ELEVATE-TN trial):

In first-line treatment, compared with bendamustine+rituximab, acotinib combined with obinutuzumab significantly prolonged progression-free survival (PFS).

3The yearPFS rate reaches more than 90%, and the side effects are significantly less than ibrutinib.

2.Zanbrutinib efficacy data (SEQUOIA and ALPINE trials):

Shows superior PFS and lower cardiotoxicity than ibrutinib.

It also shows good response rates and survival advantages in high-risk patients (such as 17p deletion).

Overall, the two are similar in efficacy, and both are significantly better than the first generation BTK inhibitors. Zanubrutinib has more data in patients with certain high-risk mutations, while acotinib has accumulated more clinical experience in combination therapy.

4. Comparison of safety and adverse reactions

Compared with ibrutinib, both acotinib and zanubrutinib greatly reduce the risk of cardiotoxicity and bleeding, but there are still subtle differences.

1.Common adverse reactions of acotinib:

Headache (common but usually mild)

Risk of infection (especially respiratory infections)

Rare, but you should be wary of bleeding and irregular heartbeat

2.Common adverse reactions of zanubrutinib:

Neutropenia, rash, diarrhea, etc.

The incidence of atrial fibrillation is lower than that of acotinib and ibrutinib

Overall well tolerated and suitable for long-term medication

If the patient has underlying cardiovascular diseases, such as hypertension, atrial fibrillation, etc., zanubrutinib may be safer; and for patients pursuing higher blood drug stability, acotinib is also a first choice.

5. Indications, medical insurance coverage and price differences

Currently, acotinib has been launched in China and is included in medical insurance, and is suitable for:

Relapse/RefractoryCLL/SLL

Mantle cell lymphoma (in some countries)

Zanubrutinib has a wider range of indications:

Approved forCLL/SLL, MCL, Waldenstrom's macroglobulinemia, etc.

It has also been included in China's medical insurance directory, and patients can enjoy a higher proportion of reimbursement.

In terms of price:

The price of domestic original drug acotinib after medical insurance is still high, with each box priced at around 2 yuan.

Due to local research and development, the price of zanubrutinib after medical insurance is more affordable. The monthly out-of-pocket cost for patients is several thousand yuan, and the financial burden is relatively low.

Both acotinib and zanubrutinib are second-generation highly selective BTK inhibitors with comparable efficacy and similar mechanisms. They are both key oral targeted drugs for the treatment of CLL, MCL and other diseases.

If patients pay more attention to the stability of efficacy and long-term combination treatment data, acotinib is a reliable choice;

If patients are more concerned about cardiac safety, affordability, and convenience, zanubrutinib may be more suitable.

The final medication selection should be made by the doctor based on the patient's individual condition, comorbid symptoms, financial status and medication history. At a time when BTK inhibitors are booming, acotinib and zanubrutinib provide more personalized and precise treatment paths for patients with B cell malignancies.

Reference materials:https://www.drugs.com